1. Mills, K.T., Xu, Y., Zhang, W., Bundy, J.D., Chen, C.S., Kelly, T.N., Chen, J., and He, J.
(2015). A systematic analysis of worldwide population-based data on the global
burden of chronic kidney disease in 2010. Kidney Int. 88, 950–957.
7. Inoue, T., Kozawa, E., Okada, H., Inukai, K., Watanabe, S., Kikuta, T., Watanabe, Y.,
Takenaka, T., Katayama, S., Tanaka, J., and Suzuki, H. (2011). Noninvasive evaluation
of kidney hypoxia and fibrosis using magnetic resonance imaging. J. Am. Soc.
Nephrol. 22, 1429–1434.
9. Lovisa, S., LeBleu, V.S., Tampe, B., Sugimoto, H., Vadnagara, K., Carstens, J.L., Wu,
C.C., Hagos, Y., Burckhardt, B.C., Pentcheva-Hoang, T., et al. (2015). Epithelial-tomesenchymal transition induces cell cycle arrest and parenchymal damage in renal
fibrosis. Nat. Med. 21, 998–1009.
10. Li, J., Xuan, Z., and Liu, C. (2013). Long non-coding RNAs and complex human diseases. Int. J. Mol. Sci. 14, 18790–18808.
11. Adams, B.D., Parsons, C., Walker, L., Zhang, W.C., and Slack, F.J. (2017). Targeting
noncoding RNAs in disease. J. Clin. Invest. 127, 761–771.
12. Jia, H., Ma, T., and Hao, C. (2020). Identification of candidate lncRNA biomarkers for
renal fibrosis: a systematic review. Life Sci. 262, 118566.
13. Fawzy, M.S., Abu AlSel, B.T., Al Ageeli, E., Al-Qahtani, S.A., Abdel-Daim, M.M., and
Toraih, E.A. (2020). Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary crosssectional analysis. Arch. Physiol. Biochem. 126, 172–182.
14. Geng, F., Liu, W., and Yu, L. (2019). Potential role of circulating long noncoding RNA
MALAT1 in predicting disease risk, severity, and patients’ survival in sepsis. J. Clin.
Lab. Anal. 33, e22968.
15. Li, Z., Yu, Z., Meng, X., and Yu, P. (2018). LncRNA LINC00968 accelerates the proliferation and fibrosis of diabetic nephropathy by epigenetically repressing p21 via recruiting EZH2. Biochem. Biophys. Res. Commun. 504, 499–504.
16. Lu, L., Liu, L.P., Zhao, Q.Q., Gui, R., and Zhao, Q.Y. (2021). Identification of a ferroptosis-related LncRNA signature as a novel prognosis model for lung adenocarcinoma.
Front. Oncol. 11, 675545.
17. Zhou, J., and Jiang, H. (2019). Livin is involved in TGF-b1-induced renal tubular
epithelial-mesenchymal transition through lncRNA-ATB. Ann. Transl. Med. 7, 463.
18. Gu, Y.Y., Dou, J.Y., Huang, X.R., Liu, X.S., and Lan, H.Y. (2021). Transforming
growth factor-b and long non-coding RNA in renal inflammation and fibrosis.
Front. Physiol. 12, 684236.
19. Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., and Tamayo,
P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection.
Cell Syst. 1, 417–425.
20. Zhao, C., Xu, Z., Wang, Z., Suo, C., Tao, J., Han, Z., Gu, M., and Tan, R. (2018). Role
of tumor necrosis factor-a in epithelial-to-mesenchymal transition in transplanted
kidney cells in recipients with chronic allograft dysfunction. Gene 642, 483–490.
21. Reich, H.N., Landolt-Marticorena, C., Boutros, P.C., John, R., Wither, J., Fortin, P.R.,
Yang, S., Scholey, J.W., and Herzenberg, A.M. (2011). Molecular markers of injury in
kidney biopsy specimens of patients with lupus nephritis. J. Mol. Diagn. 13, 143–151.
22. Bombelli, S., Meregalli, C., Scalia, C., Bovo, G., Torsello, B., De Marco, S., Cadamuro,
M., Viganò, P., Strada, G., Cattoretti, G., et al. (2018). Nephrosphere-derived cells are
induced to multilineage differentiation when cultured on human decellularized kidney scaffolds. Am. J. Pathol. 188, 184–195.
2. Djudjaj, S., and Boor, P. (2019). Cellular and molecular mechanisms of kidney
fibrosis. Mol. Aspect. Med. 65, 16–36.
23. Langner, C., Ratschek, M., Rehak, P., Schips, L., and Zigeuner, R. (2004). Expression
of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod. Pathol. 17, 180–188.
3. Liu, Y. (2011). Cellular and molecular mechanisms of renal fibrosis. Nat. Rev.
Nephrol. 7, 684–696.
24. Meng, X.M., Nikolic-Paterson, D.J., and Lan, H.Y. (2016). TGF-b: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325–338.
4. Edeling, M., Ragi, G., Huang, S., Pavenstädt, H., and Susztak, K. (2016).
Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and
Hedgehog. Nat. Rev. Nephrol. 12, 426–439.
25. Tang, P.C.T., Chan, A.S.W., Zhang, C.B., García Córdoba, C.A., Zhang, Y.Y., To, K.F.,
Leung, K.T., Lan, H.Y., and Tang, P.M.K. (2021). TGF-b1 signaling: immune dynamics of chronic kidney diseases. Front. Med. 8, 628519.
5. Zeisberg, M., and Kalluri, R. (2004). The role of epithelial-to-mesenchymal transition
in renal fibrosis. J. Mol. Med. (Berl.) 82, 175–181.
26. Nangaku, M. (2006). Chronic hypoxia and tubulointerstitial injury: a final common
pathway to end-stage renal failure. J. Am. Soc. Nephrol. 17, 17–25.
Molecular Therapy: Nucleic Acids Vol. 31 March 2023
149
Molecular Therapy: Nucleic Acids
27. Wei, X., Zhu, X., Jiang, L., Huang, X., Zhang, Y., Zhao, D., and Du, Y. (2020). Recent
advances in understanding the role of hypoxia-inducible factor 1a in renal fibrosis.
Int. Urol. Nephrol. 52, 1287–1295.
28. Kushida, N., Nomura, S., Mimura, I., Fujita, T., Yamamoto, S., Nangaku, M., and
Aburatani, H. (2016). Hypoxia-inducible factor-1a activates the transforming growth
factor-b/SMAD3 pathway in kidney tubular epithelial cells. Am. J. Nephrol. 44,
276–285.
29. Ma, L.J., and Fogo, A.B. (2009). PAI-1 and kidney fibrosis. Front. Biosci. 14,
2028–2041.
30. Ghosh, A.K., and Vaughan, D.E. (2012). PAI-1 in tissue fibrosis. J. Cell. Physiol. 227,
493–507.
31. Krag, S., Danielsen, C.C., Carmeliet, P., Nyengaard, J., and Wogensen, L. (2005).
Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced
kidney disease. Kidney Int. 68, 2651–2666.
32. Hung, T.W., Tsai, J.P., Lin, S.H., Lee, C.H., Hsieh, Y.H., and Chang, H.R. (2016).
Pentraxin 3 activates JNK signaling and regulates the epithelial-to-mesenchymal
transition in renal fibrosis. Cell. Physiol. Biochem. 40, 1029–1038.
33. Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D.W., Woodward, M., Levin, A., Zhang,
H., and Wang, H.; TESTING Study Group (2012). Corticosteroid therapy in IgA nephropathy. J. Am. Soc. Nephrol. 23, 1108–1116.
34. Matsumoto, A., Matsui, I., Katsuma, Y., Yasuda, S., Shimada, K., Namba-Hamano, T.,
Sakaguchi, Y., Kaimori, J.Y., Takabatake, Y., Inoue, K., and Isaka, Y. (2021).
Quantitative analyses of foot processes, mitochondria, and basement membranes
by structured illumination microscopy using elastica-masson- and periodic-acidschiff-stained kidney sections. Kidney Int. Rep. 6, 1923–1938.
35. Urushihara, M., Seki, Y., Tayama, T., Nagai, T., Kinoshita, Y., Jamba, A., Kondo, S.,
and Kagami, S. (2013). Glomerular angiotensin-converting enzyme 2 in pediatric IgA
nephropathy. Am. J. Nephrol. 38, 355–367.
36. Tanaka, K., Sugiyama, H., Yamanari, T., Mise, K., Morinaga, H., Kitagawa, M.,
Onishi, A., Ogawa-Akiyama, A., Tanabe, K., Eguchi, J., et al. (2018). Renal expression
150
Molecular Therapy: Nucleic Acids Vol. 31 March 2023
of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy. Nephrology 23, 855–862.
37. Reich, H.N., Troyanov, S., Scholey, J.W., and Cattran, D.C.; Toronto
Glomerulonephritis Registry (2007). Remission of proteinuria improves prognosis
in IgA nephropathy. J. Am. Soc. Nephrol. 18, 3177–3183.
38. Khan, S., Cabral, P.D., Schilling, W.P., Schmidt, Z.W., Uddin, A.N., Gingras, A.,
Madhavan, S.M., Garvin, J.L., and Schelling, J.R. (2018). Kidney proximal tubule
Lipoapoptosis is regulated by fatty acid transporter-2 (FATP2). J. Am. Soc.
Nephrol. 29, 81–91.
39. Xing, L., Chang, X., Shen, L., Zhang, C., Fan, Y., Cho, C., Zhang, Z., and Jiang, H.
(2021). Progress in drug delivery system for fibrosis therapy. Asian J. Pharm. Sci.
16, 47–61.
40. Shen, M., Pan, X., Gao, Y., Ye, H., Zhang, J., Chen, Y., Pan, M., Huang, W., Xu, X.,
Zhao, Y., and Jin, L. (2022). LncRNA CRNDE exacerbates IgA nephropathy progression by promoting NLRP3 inflammasome activation in macrophages. Immunol.
Invest. 51, 1515–1527.
41. Guo, N., Zhou, Q., Huang, X., Yu, J., Han, Q., Nong, B., Xiong, Y., Liang, P., Li, J.,
Feng, M., et al. (2020). Identification of differentially expressed circulating exosomal
lncRNAs in IgA nephropathy patients. BMC Immunol. 21, 16.
42. Zuo, N., Li, Y., Liu, N., and Wang, L. (2017). Differentially expressed long non-coding
RNAs and mRNAs in patients with IgA nephropathy. Mol. Med. Rep. 16, 7724–7730.
43. Wang, P., Luo, M.L., Song, E., Zhou, Z., Ma, T., Wang, J., Jia, N., Wang, G., Nie, S.,
Liu, Y., and Hou, F. (2018). Long noncoding RNA lnc-TSI inhibits renal fibrogenesis
by negatively regulating the TGF-b/Smad3 pathway. Sci. Transl. Med. 10, eaat2039.
44. Liang, Y., Chen, X., Wu, Y., Li, J., Zhang, S., Wang, K., Guan, X., Yang, K., and Bai, Y.
(2018). LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis
through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ. 25, 1980–1995.
45. Necsulea, A., Soumillon, M., Warnefors, M., Liechti, A., Daish, T., Zeller, U., Baker,
J.C., Grützner, F., and Kaessmann, H. (2014). The evolution of lncRNA repertoires
and expression patterns in tetrapods. Nature 505, 635–640.
...